Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23712487 | 1.00 | LPL (0.36) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL12092030 | 0.86 | LPL (0.36) | LPLLIPGP2RX7 | |
| SCHEMBL24457832 | 0.84 | JAK2 (0.35) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL18949792 | 0.83 | BACE1 (0.36) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL23206151 | 0.83 | LPL (0.34) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL8236344 | 0.82 | LPL (0.36) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL22190744 | 0.81 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL25503944 | 0.81 | LPL (0.42) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL16815439 | 0.81 | LPL (0.40) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL23409514 | 0.80 | LPL (0.37) | LPLLIPGJAK2BTKP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| WO-2023039505-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | LPL 1879/4885LIPG 627/4885JAK2 1020/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | LPL 3153/4885LIPG 2095/4885JAK2 1502/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | LPL 3630/4885LIPG 3080/4885JAK2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.